title: Dabigatran etexilate (Pradaxa®) for preventing warfarin-induced skin necrosis in a patient with severe protein C deficiency.
authors.forename: Cedric
authors.initials: C
authors.lastname: Hermans
authors.forename: Stéphane
authors.initials: S
authors.lastname: Eeckhoudt
authors.forename: Catherine
authors.initials: C
authors.lastname: Lambert
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects*; D001562:Benzimidazoles / Q000627:therapeutic use*; D000069604:Dabigatran; D003875:Drug Eruptions / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D057915:Drug Substitution; D005260:Female; D006801:Humans; D009336:Necrosis; D020151:Protein C Deficiency / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D011725:Pyridines / Q000627:therapeutic use*; D012720:Severity of Illness Index; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D014859:Warfarin / Q000009:adverse effects*; D055815:Young Adult
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D011725:Pyridines; D014859:Warfarin; D000069604:Dabigatran